, Tracking Stock Market Picks
Enter Symbol:
Solta Medical Inc (SLTM) [hlAlert]

down 1.68 %

Solta Medical Inc (SLTM) rated Buy with price target $2.25 by Ascendiant Capital Markets

Posted on: Thursday,  May 2, 2013  4:25 PM ET by Ascendiant Capital Markets

Ascendiant Capital Markets rated Buy Solta Medical Inc (NASDAQ: SLTM) on 05/02/2013. Previously Ascendiant Capital Markets rated Buy Solta Medical Inc (NASDAQ: SLTM)
on 07/05/2012., when the stock price was $2.97. Since then, Solta Medical Inc has lost 1.68% as of 01/22/2014's recent price of $2.92.
If you would have followed the previous Ascendiant Capital Markets's recommendation on SLTM, you would have lost 1.68% of your investment in 566 days.

Solta Medical Inc., formerly Thermage, Inc. is engaged in designing, developing, manufacturing and marketing energy-based medical device systems for aesthetic applications. These systems are marketed under the brand names Fraxel and Thermage and are Food & Drug Administration (FDA) cleared for dermatological procedures in the applications, which include: Skin Tightening, the Thermage NXT system offers non-invasive treatment options for skin tightening and contouring, body shaping, and improvement in the appearance of cellulite; Skin Rejuvenation, the Fraxel re:fine and Fraxel re:store systems offer treatments for skin conditions such as fine lines and pigmentation.

Ascendiant Capital Markets is led by George Santana, who has nearly twenty years of equity research experience in the United States and foreign markets. During his career, Mr. Santana has been recognized six consecutive times in the Institutional Investor magazine poll of top analysts.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/2/2013 4:25 PM Buy
as of 12/31/2012
1 Week up  1.90 %
1 Month up  6.80 %
3 Months down  -14.96 %
1 YTD down  -7.61 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/5/2012 3:25 PM Buy
7/5/2012 1:25 PM Buy
2.97 3.50

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy